- Home
- MGNX vs HLP Comparison
MGNX vs HLP Comparison
Compare MGNX & HLP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGNX
- HLP
- Stock Information
- Founded
- MGNX 2000
- HLP 2021
- Country
- MGNX United States
- HLP China
- Employees
- MGNX N/A
- HLP 167
- Industry
- MGNX Biotechnology: Pharmaceutical Preparations
- HLP Industrial Machinery/Components
- Sector
- MGNX Health Care
- HLP Industrials
- Exchange
- MGNX Nasdaq
- HLP Nasdaq
- Market Cap
- MGNX 87.7M
- HLP 66.1M
- IPO Year
- MGNX 2013
- HLP 2023
- Fundamental
- Price
- MGNX $1.58
- HLP $0.86
- Analyst Decision
- MGNX Hold
- HLP
- Analyst Count
- MGNX 9
- HLP 0
- Target Price
- MGNX $5.33
- HLP N/A
- AVG Volume (30 Days)
- MGNX 1.9M
- HLP 166.7K
- Earning Date
- MGNX 08-05-2025
- HLP 06-24-2025
- Dividend Yield
- MGNX N/A
- HLP N/A
- EPS Growth
- MGNX N/A
- HLP N/A
- EPS
- MGNX N/A
- HLP N/A
- Revenue
- MGNX $154,050,000.00
- HLP $14,105,620.00
- Revenue This Year
- MGNX N/A
- HLP N/A
- Revenue Next Year
- MGNX N/A
- HLP N/A
- P/E Ratio
- MGNX N/A
- HLP N/A
- Revenue Growth
- MGNX 255.31
- HLP N/A
- 52 Week Low
- MGNX $0.99
- HLP $0.72
- 52 Week High
- MGNX $5.77
- HLP $2.25
- Technical
- Relative Strength Index (RSI)
- MGNX 51.11
- HLP 39.08
- Support Level
- MGNX $1.42
- HLP $0.77
- Resistance Level
- MGNX $2.17
- HLP $0.96
- Average True Range (ATR)
- MGNX 0.17
- HLP 0.09
- MACD
- MGNX 0.02
- HLP -0.02
- Stochastic Oscillator
- MGNX 33.33
- HLP 27.57
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.
About HLP Hongli Group Inc.
Hongli Group Inc is a cold roll-formed steel profile manufacturer in China. It customizes and manufactures cold roll-formed steel profiles for machinery and equipment in a variety of sectors, including but not limited to mining and excavation, construction, agriculture, and transportation. Geographically, the company generates the majority of its revenue from the PRC.